Live Micron Technology Inc Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow Intra-Cellular Therapies, Inc.

Get SEC filing alerts via email and in your feed for Intra-Cellular Therapies, Inc.

ITCI

Intra-Cellular Therapies, Inc.

About Intra-Cellular Therapies, Inc.

Intra-Cellular Therapies is a biopharmaceutical company specializing in the discovery, development, and commercialization of small molecule drugs targeting psychiatric and neurological disorders. Its portfolio includes FDA-approved products like CAPLYTA for schizophrenia and bipolar depression, with ongoing clinical trials for depression, bipolar disorder, autism-related irritability, and other CNS conditions. The company leverages proprietary technology platforms to develop innovative therapies addressing underserved markets.
This description was generated via AI from an annual report. Updated 9 months ago.

Latest SEC Filings from Intra-Cellular Therapies, Inc.

1
1
Intra-Cellular Therapies, Inc. Intra-Cellular Therapies Reports 47% Revenue Growth and Strategic Acquisition Agreement with Johnson & Johnson

Via official filing (AI summary) | over 1 year ago | 0 comments

2
1
Intra-Cellular Therapies, Inc. Intra-Cellular Therapies Reports 39% Year-Over-Year Revenue Growth, Net Loss Widens in Q3 2024

Via official filing (AI summary) | over 1 year ago | 0 comments